From: Cost-effectiveness of prostate cancer screening: a systematic review of decision-analytical models
Study | Model-type | Natural history model | By (TNM) stage of cancer? | TNM staging used | Differentiation by Gleason grade? | Gleason grading used | Time horizon | Deterministic sensitivity analysis | Probabilistic sensitivity analysis |
---|---|---|---|---|---|---|---|---|---|
Chilcott et al. [23] | Individual patient simulation | No | Yes | Localised (T1–2), Locally advanced (T3–4) and metastatic | Yes | (G < 7, G = 7, G > 7) | lifetime | Yes | Yes |
Heijnsdijk et al. [25] | Individual patient simulation | Yes -MISCAN | Yes | 18 stages: each tumour stage (T1,2 etc) modelled individually | Yes | (G < 7, G = 7, G > 7) | lifetime | Yes | No |
Hummel and Chilcott [24] | Individual patient simulation and cohort | No | Yes | Localised (T1–2), Locally advanced (T3–4) and metastatic | Yes | (G < 7, G = 7, G > 7) | lifetime | Yes | No |
Keller et al. [29] | Cohort model | No | Yes | Low (≤T1a), intermediate (≤T2b), high risk (>T2b) and metastatic | Yes | G ≤ 6, G ≤ 7, G > 7 | up to 70 years | Yes | Yes |
Kobayashi et al. [27] | Markov cycle tree (cohort) | No | Yes | Localised (T1–2), Locally advanced (T3–4) and metastatic | No | – | up to 80 years old | Yes | No |
Martin et al. [30] | Cohort model | No | No | None | No | – | 50 years (lifetime) | Yes | No |
Pataky et al. [26] | Individual patient simulation | Yes -adapted FHCRC | Yes | Locoregional (≤T2a vs > T2) distant disease | Assumed Yesa | Not reported | assumed lifetime | Yes | No |
Roth et al. [28] | Individual patient simulation | Yes -adapted FHCRC | Yes | Locoregional (≤T2a vs > T2) distant disease | Yesa | Indirectly (8–10/ 2–7) | lifetime | Yes | Yes |
Wolstenholme et al. [31] | Cohort model | No | Yes | Localised (T1–2), Locally advanced (T3–4) and metastatic | No | – | lifetime(100 years old) | Yes | Yes |
Shteynshlyuger & Andriole, [22] | Population based model | – | Yes | No details provided | – | – | lifetime | Yes | No |